Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Privacy Policy  
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Intranasal benzodiazepines, á2-agonists and their antagonists in canaries
Canaries sometimes require sedation or anesthesia but everybody knows that this is much more difficult and risky than in other species. Is the intranasal application an alternative that can be recommended? It seems so, as this interesting study from Iran shows.

This prospective randomized study was performed to evaluate the effects of intranasal benzodiazepines (midazolam and diazepam), á2-agonists (xylazine and detomidine) and their antagonists (flumazenil and yohimbine) in canaries.

Twenty-six healthy adult domesticated canaries of both sexes, weighing 18.3 ± 1.0 g.

In Study 1 an attempt was made to determine the dose of each drug that allowed treated canaries to be laid in dorsal recumbency for at least 5 minutes, i.e. its effective dose.

This involved the evaluation of various doses, during which equal volumes of the tested drug were administered slowly into each nostril.

In study 2 the onset of action, duration and quality of sedation induced by each drug at its effective dose were evaluated.
The efficacy of flumazenil and yohimbine in antagonizing the effects of the sedative drugs was also studied.

Results: In study 1 administration of 25 ìL per nostril diazepam (5 mg mL1 solution) or midazolam (5 mg mL1 solution) to each bird caused adequate sedation within 1–2 minutes; birds did not move when placed in dorsal recumbency.

After administration of 12 ìL per nostril of either xylazine (20 mg mL1) or detomidine (10 mg mL1), birds seemed heavily sedated and assumed sternal recumbency but could not be placed in dorsal recumbency.

Higher doses of xylazine (0.5 mg per nostril) or detomidine (0.25 mg per nostril) prolonged sedation but did not produce dorsal recumbency.

In study 2 in all treatment groups, onset of action was rapid.
Duration of dorsal recumbency was significantly longer (p < 0.05) with diazepam (38.4 ± 10.5 minutes) than midazolam (17.1 ± 2.2 minutes).

Intranasal flumazenil (2.5 ìg per nostril) significantly reduced recumbency time. Duration of sedation was longer with á2-agonists compared with benzodiazepines.

Detomidine had the longest duration of effect (257.5 ± 1.5 minutes) and midazolam the shortest (36.9 ± 2.4 minutes).

Nasally administered flumazenil significantly reduced the duration of sedation with diazepam and midazolam while yohimbine (120 ìg per nostril) effectively antagonized the effects of xylazine and detomidine.

Conclusion: Intranasal benzodiazepines produce rapid and effective sedation in canaries. Intranasal á2 agonists produce sedation but not sustained recumbency. Specific antagonists are also effective when used by this route.

Based on these results, intranasal sedative drug administration is an acceptable alternative method of drug delivery in canaries.



Source: Vesal, Nasser & Zare, Payman (2006): Clinical evaluation of intranasal benzodiazepines, á2-agonists and their antagonists in canaries. In: Veterinary Anaesthesia and Analgesia 33 (3), 143-148.




Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Novel intratumoral therapy in canine transmissible venereal tumourmembers
Canine transmissible venereal tumour (CTVT) is a naturally occurring contagious neoplasm of dogs located mainly on the external genitalia of both sexes. The course of vincristine chemotherapy, the most effective and practical therapy, is affected by the immune status of the host. The aim was to investigate recombinant human interferon alpha‐2a (rhIFNα‐2a) and vincristine for treatment of CTVT.

  • Long-term outcome of dogs with primary immune-mediated thrombocytopeniamembers
  • Insulin treatment and IGF-I in cats with diabetes mellitusmembers
  • Color doppler ultrasound in neoplastic and non-neoplastic canine testicles members
  • Computed tomographic arthrography of the canine shoulder joint members
  • Prognostic scoring system for dogs managed with hemodialysismembers
  • Sonography vs percutaneous palpation to identify targeted thoracolumbar intervertebral disc spacesmembers
  • Distribution of alveolar-interstitial syndrome in dogs and cats with respiratory distress members
  • Disorders of sex development in catsmembers
  • Core ocular surface microbiome in dogsmembers
  • ACVIM small animal consensus statement on safe use of cytotoxic chemotherapeutics members
  • MRI imaging of masticatory muscles in basset houndsmembers
  • Mucosal microbiota, gastrointestinal inflammation and small cell intestinal lymphoma in cats members


  • [ Home ] [ About ] [ Contact / Request ] [ Privacy Policy ]

    Copyright © 2001-2018 VetContact GmbH
    All rights reserved